NEW YORK, Dec. 29, 2025 /PRNewswire/ — MMMera, Inc., a privately held intellectual property and digital brand development company, announced today that it has retainedNEW YORK, Dec. 29, 2025 /PRNewswire/ — MMMera, Inc., a privately held intellectual property and digital brand development company, announced today that it has retained

CND-SA (Consolidated Strategic Advisors) retained as Strategic Advisor to MMMera, Inc. to strengthen Institutional Positioning Across Guillotine® and Digital IP Portfolio

2025/12/30 06:45
2 min read
For feedback or concerns regarding this content, please contact us at [email protected]

NEW YORK, Dec. 29, 2025 /PRNewswire/ — MMMera, Inc., a privately held intellectual property and digital brand development company, announced today that it has retained CND-SA (Consolidated Strategic Advisors) as strategic advisor to support institutional positioning, governance, and long-range execution planning across its portfolio, including the continued development of Guillotine®, its flagship electronic gaming property.

Guillotine® is a proprietary gaming IP developed within MMMera’s broader creative portfolio. Built around interactive gameplay and narrative-driven mechanics, the platform reflects MMMera’s commitment to developing original digital entertainment assets designed for scalable deployment and long-term franchise potential.

MMMera is led by Marcus Maximus Mera, Founder and Chief Executive Officer, whose creative work informs the conceptual foundation of the company’s gaming and digital properties. MMMera’s approach blends digital art, world-building, and interactive design, serving as the creative engine behind Guillotine® and related assets.

“This engagement with CND-SA marks an important step in professionalizing Guillotine® and MMMera’s broader electronic gaming portfolio,” said Mera. “I am excited to work with Karl Reeves and the CND-SA team as we continue strengthening our intellectual property strategy and establishing the institutional framework needed for scale while preserving the creative integrity of our work.”

Under the engagement, CND-SA will advise MMMera on corporate strategy, governance, intellectual property structuring, and execution planning as the company advances Guillotine® and other electronic gaming initiatives.

“We are very pleased to be working with Marcus,” said Karl Reeves, Chief Executive Officer of CND-SA. “Guillotine® represents a compelling example of artist-led original gaming IP. Our role is to help MMMera translate that creative foundation into an institutional-grade platform without diluting its originality.”

MMMera, Inc. is a privately held company focused on the development, management, and strategic positioning of proprietary intellectual property, with concentration on electronic gaming and digital creative assets.

Guillotine® is an electronic gaming property developed within the MMMera portfolio as part of the company’s artist-led approach to interactive digital entertainment.

CND-SA (Consolidated Strategic Advisors) is an independent strategic advisory firm providing founder-level counsel in complex corporate, intellectual property, and high-stakes strategic engagements.

Media Contact
Hannah Morgan
[email protected]
p: 212-757-1470
f: 212-757-6678

CND-SA (Consolidated Strategic Advisors)
747 Third Avenue, 11th Floor
New York, NY 10017

Cision View original content:https://www.prnewswire.com/news-releases/cnd-sa-consolidated-strategic-advisors-retained-as-strategic-advisor-to-mmmera-inc-to-strengthen-institutional-positioning-across-guillotine-and-digital-ip-portfolio-302650344.html

SOURCE Consolidated Strategic Advisory LLC

Market Opportunity
Story Logo
Story Price(IP)
$0.8291
$0.8291$0.8291
-2.81%
USD
Story (IP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09